Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transfus Med Rev ; 25(3): 206-16, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21377319

ABSTRACT

The transfusion of red blood cells (RBCs) is now considered a well-settled and essential therapy. However, some difficulties and constraints still occur, such as long-term blood product shortage, blood donor population aging, known and yet unknown transfusion-transmitted infectious agents, growing cost of the transfusion supply chain management, and the inescapable blood group polymorphism barrier. Red blood cells can be now cultured in vitro from human hematopoietic, human embryonic, or human-induced pluripotent stem cells (hiPSCs). The highly promising hiPSC technology represents a potentially unlimited source of RBCs and opens the door to the revolutionary development of a new generation of allogeneic transfusion products. Assuming that in vitro large-scale cultured RBC production efficiently operates in the near future, we draw here some futuristic but realistic scenarios regarding potential applications for alloimmunized patients and those with a rare blood group. We retrospectively studied a cohort of 16,486 consecutive alloimmunized patients (10-year period), showing 1 to 7 alloantibodies with 361 different antibody combinations. We showed that only 3 hiPSC clones would be sufficient to match more than 99% of the 16,486 patients in need of RBC transfusions. The study of the French National Registry of People with a Rare Blood Phenotype/Genotype (10-year period) shows that 15 hiPSC clones would cover 100% of the needs in patients of white ancestry. In addition, one single hiPSC clone would meet 73% of the needs in alloimmunized patients with sickle cell disease for whom rare cryopreserved RBC units were required. As a result, we consider that a very limited number of RBC clones would be able to not only provide for the need for most alloimmunized patients and those with a rare blood group but also efficiently allow for a policy for alloimmunization prevention in multiply transfused patients.


Subject(s)
Adult Stem Cells , Blood Banking/methods , Blood Grouping and Crossmatching/methods , Erythrocytes/physiology , Isoantibodies/immunology , Pluripotent Stem Cells , Adult , Animals , Blood Specimen Collection/methods , Cell Differentiation , Erythrocyte Transfusion/methods , Humans , Isoantibodies/adverse effects
2.
Eur J Obstet Gynecol Reprod Biol ; 146(1): 65-70, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19482403

ABSTRACT

OBJECTIVE: To assess the potential impact of new guidelines recommending routine antenatal prophylaxis at 28 weeks of pregnancy on incidence, consequences and cost of rhesus immunization. STUDY DESIGN: All rhesus immunizations of 224,500 ongoing pregnancies in two neighbouring administrative areas in France between 2000 and 2006 were enrolled in this retrospective study. To determine the aetiology of immunization and to specify when sensitization occurred, we searched sensitizing events between the last negative and the first positive red-cell antibody test results. Perinatal consequences and costing were also analyzed. RESULTS: From 138 rhesus negative women bearing anti-D antibodies, none had received routine prophylaxis at 28 weeks. 37% were primary immunizations and 63% were reactivating former immunization. 63% sensitizations occurred after unprovoked foetal-maternal haemorrhage, mostly after 28 weeks (54%). Twenty-five (18.1%) sensitizations resulted from inappropriate management of existing prophylaxis. Immigrants with previously acquired antibodies accounted for 10% of cases. There was no foetal demise and none born before 28 weeks among our 140 babies. Only 25% required intensive care, mostly those born to mothers reactivating immunization, with an overall good perinatal outcome. Systematic 28-week prophylaxis would have cost about euro 2.5 million to reduce overall cost of immunizations by euro 0.6 million. CONCLUSIONS: The incidence of rhesus immunization in our population was low at 0.41 per thousand. Routine antenatal prophylaxis could have avoided 54% of these immunizations but expected perinatal benefits are low, as newborns with the worst issue were born to mothers with unavoidable immunizations. Therefore the cost-effectiveness of this strategy is doubtful.


Subject(s)
Rh Isoimmunization/prevention & control , Adolescent , Adult , Cost-Benefit Analysis , Female , Fetomaternal Transfusion/drug therapy , Fetomaternal Transfusion/immunology , France/epidemiology , Humans , Infant, Newborn , Isoantibodies/economics , Pregnancy , Pregnancy Complications, Hematologic/immunology , Retrospective Studies , Rh Isoimmunization/economics , Rh Isoimmunization/epidemiology , Rh Isoimmunization/immunology , Rh-Hr Blood-Group System/immunology , Rho(D) Immune Globulin
3.
Transfusion ; 42(5): 627-33, 2002 May.
Article in English | MEDLINE | ID: mdl-12084172

ABSTRACT

BACKGROUND: D(C)(e) and D(C)e haplotypes may be encountered in the white population. Few data are available on the molecular backgrounds responsible for depressed expression of C and e. STUDY DESIGN AND METHODS: Individuals of white origin carrying a D(C)(e) genotype resulting in depressed expression of C or both C and e were subdivided into two categories based on the RBC reactivity with the human sera Mol and Hor, which contain antibodies against low-frequency antigens of the Rh (RH) system and other non-Rh low-frequency antigens. Neither Hor+, Mol+ nor Hor+, Mol- RBCs expressed the V (RH10), VS (RH20), and/or Rh32 (RH32) low-frequency antigens. These results suggested that Hor+, Mol+ variants expressed Rh33 (RH33 or Har) and FPTT (RH50), whereas Hor+, Mol- variants might express an undefined low-frequency antigen. Further serologic and molecular analyses were performed. RESULTS: Molecular analysis of Hor+, Mol+ variants revealed a hybrid gene structure RHCe-D(5)-Ce, in which exon 5 of RHCE (RHCe allele) was replaced by exon 5 of RHD (the so-called RHCeVA allele). The presence of exon 5RHD resulted in several amino acid alterations predicted in the external loop 4 of the CeVA polypeptide. Molecular analysis of Hor+, Mol- variants revealed the presence of a new RHCe allele characterized by a single point mutation C340T within exon 3 (the so-called RHCeMA allele), resulting in a R114W substitution predicted on the external loop 2 of the CeMA polypeptide. A serologic study showed a different pattern of reactivity with C and e MoAbs. CONCLUSION: Two types of mutations resulted in amino acid substitutions predicted in external loops 4 and 2, respectively, which altered both the C and e reactivity, and indicated conformation changes or defective interaction between nonadjacent loops of the Ce polypeptide. Serologic analysis showed that together with Hor and Mol sera testing, the use of different C and e MoAbs could help to identify these variants within the white population.


Subject(s)
Glycoproteins/genetics , Haplotypes/genetics , Oncogene Proteins, Fusion/genetics , Recombinant Fusion Proteins , Rh-Hr Blood-Group System/genetics , White People/genetics , Alleles , Amino Acid Substitution , Antibodies, Monoclonal/immunology , Blood Grouping and Crossmatching , DNA Mutational Analysis , Exons/genetics , Female , Gene Expression Regulation , Genes , Glycoproteins/biosynthesis , Glycoproteins/immunology , Humans , Male , Models, Molecular , Oncogene Proteins, Fusion/biosynthesis , Oncogene Proteins, Fusion/immunology , Pedigree , Polymorphism, Genetic , Reverse Transcriptase Polymerase Chain Reaction , Rh-Hr Blood-Group System/biosynthesis , Rh-Hr Blood-Group System/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...